
Opinion|Videos|June 3, 2025
VIDEO: Addressing Iron Deficiency Anemia in Women’s Health: Insights for the OB/GYN Practice
Author(s)Steven Fein, MD, MPH, Ashley Benson, MD
Panelists discuss how understanding the causes of iron deficiency in pregnancy, selecting appropriate supplementation strategies, and collaborating between obstetrician-gynecologists and hematologists are crucial for effective management and ensuring optimal care for pregnant women.
Advertisement
Advertisement
Related to this article

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.
Advertisement
Advertisement
Trending on HCPLive
1
Upadacitinib Response Within Days in Crohn’s Disease, With Raja Atreya, MD
2
Stepwise Chronic Spontaneous Urticaria Management, With Timothy Craig, DO
3
Ultra-Processed Food Intake Increases Risk of HF in All Phenotypes
4
Top Videos From 2026 Dermatology Meetings: 12 Expert Interviews to Watch
5

